BRPI0408946A - material biologicamente ativo conjugado com polìmero biocompatìvel com complexo 1:1, seu processo de preparação e composição farmacêutica compreendendo o mesmo - Google Patents

material biologicamente ativo conjugado com polìmero biocompatìvel com complexo 1:1, seu processo de preparação e composição farmacêutica compreendendo o mesmo

Info

Publication number
BRPI0408946A
BRPI0408946A BRPI0408946-4A BRPI0408946A BRPI0408946A BR PI0408946 A BRPI0408946 A BR PI0408946A BR PI0408946 A BRPI0408946 A BR PI0408946A BR PI0408946 A BRPI0408946 A BR PI0408946A
Authority
BR
Brazil
Prior art keywords
biologically active
biocompatible polymer
pharmaceutical composition
active material
same
Prior art date
Application number
BRPI0408946-4A
Other languages
English (en)
Inventor
Myung-Ok Park
Original Assignee
Biopolymed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020040007983A external-priority patent/KR20040086521A/ko
Application filed by Biopolymed Inc filed Critical Biopolymed Inc
Publication of BRPI0408946A publication Critical patent/BRPI0408946A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"MATERIAL BIOLOGICAMENTE ATIVO CONJUGADO COM POLìMERO BIOCOMPATìVEL COM COMPLEXO 1:1, SEU PROCESSO DE PREPARAçãO E COMPOSIçãO FARMACêUTICA COMPREENDENDO O MESMO". A presente invenção refere-se a conjugados de polímeros biocompatíveis e moléculas biologicamente ativas onde o polímero biocompatível ativado está conjugado a um grupo carboxila de material biologicamente ativo em uma razão molar de 1:1 e processos de sua preparação e uma composição farmacêutica compreendendo os mesmos.
BRPI0408946-4A 2003-03-28 2004-03-27 material biologicamente ativo conjugado com polìmero biocompatìvel com complexo 1:1, seu processo de preparação e composição farmacêutica compreendendo o mesmo BRPI0408946A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20030019734 2003-03-28
KR1020040007983A KR20040086521A (ko) 2003-03-28 2004-02-06 생물학적 활성물질과 생체적합성 고분자의 1:1 접합체,이의 제조방법과 이를 함유하는 약학 조성물
PCT/KR2004/000701 WO2004084948A1 (en) 2003-03-28 2004-03-27 Biologically active material conjugated with biocompatible polymer with 1:1 complex, preparation method thereof and pharmaceutical composition comprising the same

Publications (1)

Publication Number Publication Date
BRPI0408946A true BRPI0408946A (pt) 2006-04-04

Family

ID=36118393

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0408946-4A BRPI0408946A (pt) 2003-03-28 2004-03-27 material biologicamente ativo conjugado com polìmero biocompatìvel com complexo 1:1, seu processo de preparação e composição farmacêutica compreendendo o mesmo

Country Status (8)

Country Link
US (2) US20050059129A1 (pt)
EP (1) EP1608408A4 (pt)
JP (1) JP2006521372A (pt)
AU (1) AU2004224466B2 (pt)
BR (1) BRPI0408946A (pt)
CA (1) CA2530725A1 (pt)
MX (1) MXPA05010411A (pt)
WO (1) WO2004084948A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2788505C (en) 2003-02-26 2018-09-04 Nektar Therapeutics Polymer-factor viii moiety conjugates
WO2005039641A2 (en) * 2003-10-15 2005-05-06 The Regents Of The University Of California Biomacromolecule polymer conjugates
KR100759130B1 (ko) * 2005-02-12 2007-09-19 휴메드 주식회사 항 인테그린 항체 코팅스텐트 및 그의 제조방법
BRPI0711016A2 (pt) * 2006-05-17 2011-08-23 E.I. Du Pont De Nemours And Company composição de cuidado pessoal e gel
AU2008323768A1 (en) * 2007-11-09 2009-05-14 Baxter Healthcare S.A. Modified recombinant Factor VIII and von Willebrand Factor and methods of use
KR20100052730A (ko) * 2008-11-11 2010-05-20 한국유니온제약 주식회사 생체적합성 고분자와 결합한 신규한 에리스로포이에틴 접합체
EP2837392A3 (en) * 2009-09-15 2015-05-13 Kaneka Corporation Modified erythropoietin to which water-soluble long-chain molecule is added
CN103184209B (zh) * 2011-12-27 2015-09-16 拜奥生物科技（上海）有限公司 人精氨酸酶和聚乙二醇化人精氨酸酶及其应用
US10064951B2 (en) 2012-03-30 2018-09-04 Hanmi Science Co., Ltd. Liquid formulation of highly concentrated long-acting human growth hormone conjugate
EA021643B1 (ru) * 2013-03-28 2015-07-30 Илья Александрович МАРКОВ Монопегилированный интерферон-альфа линейной структуры и фармацевтическая композиция для приготовления лекарственного средства, обладающего активностью интерферона-альфа
EA021610B1 (ru) * 2013-03-28 2015-07-30 Илья Александрович МАРКОВ Жидкое противовирусное лекарственное средство
EA023360B1 (ru) * 2013-03-28 2016-05-31 Илья Александрович МАРКОВ Линейный ацилазидный пегилирующий агент, способ его получения и способ получения пегилированного интерферона
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
US9585934B2 (en) 2014-10-22 2017-03-07 Extend Biosciences, Inc. Therapeutic vitamin D conjugates
US12233115B2 (en) 2022-09-30 2025-02-25 Extend Biosciences, Inc. Long-acting parathyroid hormone

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4640835A (en) * 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
JP2989002B2 (ja) * 1988-12-22 1999-12-13 キリン―アムジエン・インコーポレーテツド 化学修飾顆粒球コロニー刺激因子
US5766897A (en) * 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
JPH06506217A (ja) * 1991-03-18 1994-07-14 エンゾン，インコーポレーテッド ポリペプチドまたはグリコポリペプチドとポリマーとのヒドラジン含有結合体
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US5597709A (en) * 1994-01-27 1997-01-28 Human Genome Sciences, Inc. Human growth hormone splice variants hGHV-2(88) and hGHV-3(53)
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5738846A (en) * 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
US5985263A (en) * 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
HU229888B1 (en) * 1998-10-16 2014-11-28 Biogen Idec Ma Inc Cambridge Polymer conjugates of interferon betha-1a and uses
US20030171285A1 (en) * 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
JP2005517648A (ja) * 2001-12-07 2005-06-16 インターミューン インコーポレイテッド 肝炎ウイルス感染症を治療するための組成物および方法
US20050148763A1 (en) * 2002-02-01 2005-07-07 Chugai Seiyaku Kabushiki Kaisha Peg-binding pth or peg-binding pth derivative
RS20050502A (sr) * 2002-12-26 2007-08-03 Mountain View Pharmaceuticals Inc., Polimerni konjugati interferona- beta sa povećanom biološkom aktivnošću
CA2516552A1 (en) * 2003-02-26 2004-09-10 Intermune, Inc. Polyethylene glycol modified interferon compositions and methods of use thereof
WO2005067454A2 (en) * 2003-12-23 2005-07-28 Valeant Pharmaceuticals North America Combination therapy for treating hepatitis c virus infection

Also Published As

Publication number Publication date
CA2530725A1 (en) 2004-10-07
EP1608408A4 (en) 2008-02-27
MXPA05010411A (es) 2006-05-31
US20050059129A1 (en) 2005-03-17
JP2006521372A (ja) 2006-09-21
US20070117924A1 (en) 2007-05-24
EP1608408A1 (en) 2005-12-28
AU2004224466A1 (en) 2004-10-07
WO2004084948A1 (en) 2004-10-07
AU2004224466B2 (en) 2008-01-03

Similar Documents

Publication Publication Date Title
BRPI0408946A (pt) material biologicamente ativo conjugado com polìmero biocompatìvel com complexo 1:1, seu processo de preparação e composição farmacêutica compreendendo o mesmo
BRPI0412671A (pt) conjugados de um polìmero e uma proteìna ligados por um grupo de ligação de oxima
BR9903345A (pt) Emplastro cosmético, farmacêutico ou dermatológico e conjunto
BR0010750A (pt) Peptìdeos insulinotrópicos de longa duração
BRPI0613005A8 (pt) uso de polipeptídeos de aprotinina como veículos em conjugados farmacêuticos.
DE60312333D1 (de) Einen lipophilen wirkstoff enthaltende feste pharmazeutische zusammensetzung sowie deren herstellung
ATE288256T1 (de) Dermale zusammensetzungen
ECSP034855A (es) Administracion pulmonar de insulina quimicamente modificada
WO2004060405A8 (en) Tissue reactive compounds and compositions and uses thereof
GEP20022804B (en) Erythropoietin Derivatives
ATE541587T1 (de) Konjugat-additionsreaktionen zur kontrollierten abgabe von pharmazeutisch wirksamen substanzen
ATE369878T1 (de) Träger-pharmaka-konjugate
BR0208338A (pt) Derivados de piridina
WO2000064486A3 (en) Enzymatically activated polymeric drug conjugates
BRPI0309868B1 (pt) métodos de preparação de uma composição de reduzida fração conjugada inferior
ATE263579T1 (de) Abgabe von polyethylene glycol-molekül- konjugaten aus abbaubarem hydrogel
BRPI0417341A (pt) fator ix glicopeguilado
EP0787009A4 (en) CANCER-INHIBITING PEPTIDES
EP0740650A4 (en) CO-MEDICINAL PRODUCTS USED AS A REGULATED MEDICINE DELIVERY PROCESS
AU2001266033A1 (en) Formulation based on heparin, glycosaminoglycan or heparinoid, use of the formulation and the formulation base
DE602004018985D1 (de) Epsilon-Polylysin gegen Halitose
EP1305322A4 (en) DERIVATIVES OF CHAIN-DERIVED LIPOPHILES MOLECULES AND THEIR USE
DE60113445D1 (de) Substanzen mit verzweigten linkermolekülen
BR0111506A (pt) Complexos de droga macromoleculares e composições contendo os mesmos
ATE317703T1 (de) Polymer-wirkstoff-konjugate zur behandlung von krebs

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.

B15K Others concerning applications: alteration of classification

Ipc: A61K 47/60 (2017.01)